Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 32392332.
- Also identified by DOI 10.1093/cid/ciaa558 and PMC identifier 7239205.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations.
Medical subject headings
- Antiviral Agents
- COVID-19 Drug Treatment